Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H23N3O.ClH |
Molecular Weight | 261.791 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=C(CN1CCNCC1)NC2CCCCC2
InChI
InChIKey=NJIZIJFDFPHEQU-UHFFFAOYSA-N
InChI=1S/C12H23N3O.ClH/c16-12(10-15-8-6-13-7-9-15)14-11-4-2-1-3-5-11;/h11,13H,1-10H2,(H,14,16);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H23N3O |
Molecular Weight | 225.3305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Esaprazole, also known as hexaprazole, was developed in the 1980s as a drug for the treatment of gastric and duodenal ulcers. Esaprazole exerts a dose-dependent cytoprotective effect on the gastric mucosa in man. It was shown to have a dose-dependent antisecretory activity, which was particularly evident on secretion volume and acid output. Esaprazole completed phase II clinical trials with only a few minor side effects being reported, but was shown to be less effective than Cimetidine and Ranitidine at healing ulcers. Esaprazole is a weak sigma opioid receptor and muscarinic acetylcholine receptors M3 and M5 ligand. Esaprazole analogs with many compounds showing neuroprotective properties.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23601816
Curator's Comment: low brain penetration potential
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3602 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23601816 |
27.0 µM [IC50] | ||
Target ID: P08483 Gene ID: 24260.0 Gene Symbol: Chrm3 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23601816 |
87.0 µM [IC50] | ||
Target ID: CHEMBL277 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23601816 |
71.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
1350 mg 1 times / day multiple, oral Highest studied dose Dose: 1350 mg, 1 times / day Route: oral Route: multiple Dose: 1350 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Condition: gastric ulcer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
900 mg single, intravenous Highest studied dose Dose: 900 mg Route: intravenous Route: single Dose: 900 mg Sources: |
unhealthy, ADULT n = 6 Health Status: unhealthy Condition: gastrointestinal disorder Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Bis(3,5-dimethyl-pyrazol-1-yl)methane]{N-[1-(2-oxidophen-yl)ethyl-idene]-dl-alaninato}copper(II) monohydrate. | 2008 Nov 13 |
|
Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. | 2011 May |
|
Synthesis and biological evaluation of Esaprazole analogues showing σ1 binding and neuroprotective properties in vitro. | 2013 Jun 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3315535
Once a day at doses of 900 and 1350 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23601816
Esaprazole prevented cell death in a dose-dependent manner against both glutamate and peroxide-induced cell death in primary culture of cortical neurons, with a 27% and 44% decrease in cell death at concentration 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:55:41 GMT 2023
by
admin
on
Sat Dec 16 09:55:41 GMT 2023
|
Record UNII |
5T7LN77U1M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80919848
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | |||
|
91290-76-5
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | |||
|
6917681
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | |||
|
293-827-3
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | |||
|
5T7LN77U1M
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | |||
|
m1136
Created by
admin on Sat Dec 16 09:55:41 GMT 2023 , Edited by admin on Sat Dec 16 09:55:41 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |